aknemycin plus
neopharm ltd - erythromycin; tretinoin - solution - erythromycin 4 g / 100 g; tretinoin 0.025 g / 100 g - erythromycin, combinations - erythromycin, combinations - all forms of acne, both non-inflammatory forms with comedones and inflammatory forms with papules and pustules, particularly in the case of fat-rich skin.
ebastel oral solution
almirall s.a. ronda general mitre 151 08022 barcelona(spain) - ebastine - oral solution - 1 mg of ebastine 1 ml - other antihistamines for systemic use
skilarence
almirall s.a - dimethyl fumarate - psoriasis - immunosuppressants - skilarence is indicated for the treatment of moderate to severe plaque psoriasis in adults in need of systemic medicinal therapy.
aknemycin plus solution
lexon (uk) ltd - erythromycin; tretinoin - cutaneous solution - 40mg/1gram ; 250microgram/1gram
balneum plus cream
waymade healthcare plc - urea; lauromacrogols - cutaneous cream - 50mg/1gram ; 30mg/1gram
ilumetri
almirall s.a - tildrakizumab - psoriasis - immunosuppressants, interleukin inhibitors, - ilumetri is indicated for the treatment of adults with moderate to severe plaque psoriasis who are candidates for systemic therapy.
diclofenac sodium gel
e. fougera & co. a division of fougera pharmaceuticals inc. - diclofenac sodium (unii: qtg126297q) (diclofenac - unii:144o8ql0l1) - diclofenac sodium gel is indicated for the topical treatment of actinic keratoses (ak). sun avoidance is indicated during therapy. diclofenac sodium gel is contraindicated in patients with a known hypersensitivity to diclofenac, benzyl alcohol, polyethylene glycol monomethyl ether 350 and/or hyaluronate sodium. diclofenac sodium gel is contraindicated in the following patients: - in the setting of coronary artery bypass graft (cabg) surgery.
balneum plus cream
mawdsley-brooks & company ltd - urea; lauromacrogols - cutaneous cream - 50mg/1gram ; 30mg/1gram
balneum plus cream
de pharmaceuticals - urea; lauromacrogols - cutaneous cream - 50mg/1gram ; 30mg/1gram
ebglyss
almirall, s.a. - lebrikizumab - dermatitis, atopic - other dermatological preparations - ebglyss is indicated for the treatment of moderate-to-severe atopic dermatitis in adults and adolescents 12 years and older with a body weight of at least 40 kg who are candidates for systemic therapy.